The Potential Role of LRG1 in Hepatosteatosis and Insulin Resistance in Obese Children

What is already known on this topic?•LRG1 has emerged as an adipokine implicated in obesity-related metabolic dysfunction, particularly in adult populations.•Adult studies have generally reported higher circulating LRG1 levels in association with IR, dyslipidemia, and cardiometabolic risk.•The evidence regarding LRG1 in pediatric obesity is limited, and its relationship with hepatosteatosis and IR in children remains unclear.•Adiponectin is consistently linked to improved insulin sensitivity and a favorable metabolic profile, whereas TNF-α is a key proinflammatory cytokine associated with obesity-related low-grade inflammation.•A combined assessment of adipokines/cytokines may provide a more comprehensive view of metabolic derangements in childhood obesity. What this study adds?•This study is among the first to comprehensively evaluate LRG1 in pediatric obesity with respect to hepatosteatosis and IR.•The finding of lower LRG1 levels in insulin-resistant children contrasts with adult data, indicating distinct, age-specific pathophysiological mechanisms.•The results highlight that LRG1 may act not merely as an inflammatory marker but as a complex metabolic regulator during growth and development.